- Home
- AVTX vs SGMT Comparison
AVTX vs SGMT Comparison
Compare AVTX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVTX | SGMT |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 238.7M |
| IPO Year | 2015 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AVTX | SGMT |
|---|---|---|
| Price | $19.09 | $5.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $32.29 | $29.71 |
| AVG Volume (30 Days) | 298.2K | ★ 618.3K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $192,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.39 | $1.73 |
| 52 Week High | $20.72 | $11.41 |
Technical Indicators
Market Signals| Indicator | AVTX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 38.47 |
| Support Level | $17.18 | $5.77 |
| Resistance Level | $20.20 | $6.93 |
| Average True Range (ATR) | 1.72 | 0.44 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 69.94 | 22.57 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.